文献速递炎症性肠病消化内镜

无创生物标志物与影像学评估克罗恩病术后复发的诊断准确性

Diagnostic Accuracy of Noninvasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-06-02

该系统综述与荟萃分析纳入17项研究(N=1080)评估炎症生物标志物、20项研究(N=1053)评估影像学检查,对比结肠镜检测克罗恩病术后内镜复发的诊断准确性。粪便钙卫蛋白(阈值50 μg/g)敏感性0.76、特异性0.66,CTE/MRE敏感性0.89、特异性0.65,IUS敏感性0.92、特异性0.76,优化IUS参数后特异性提高至0.85。

要点

  • 粪便钙卫蛋白(阈值50 μg/g)敏感性0.76(95%CI 0.70-0.82),特异性0.66(95%CI 0.56-0.75)。
  • CTE/MRE敏感性0.89(95%CI 0.73-0.96)、特异性0.65(95%CI 0.43-0.82)。
  • IUS敏感性0.92(95%CI 0.75-0.96)、特异性0.76(95%CI 0.52-0.90);优化参数后特异性0.85(95%CI 0.71-0.93)。

核心结论

  • 粪便钙卫蛋白(<50 μg/g)和横断面影像学的高敏感性有助于减少克罗恩病术后复发监测中对有创且昂贵结肠镜的需求。
  • 采用IUS参数的优化超声复发定义可能进一步提高特异性,从而无需内镜即可做出治疗决策。

研究设计与样本

  • 系统综述与荟萃分析,检索至2024年1月31日,纳入评估CRP、粪便钙卫蛋白、CTE/MRE或IUS对比结肠镜检测克罗恩病复发的诊断准确性研究。
  • 17项研究(N=1080)评估炎症生物标志物,20项研究(N=1053)评估影像学检查。
  • 采用随机效应分层汇总受试者工作特征模型汇总敏感性、特异性及阳性/阴性似然比。

主要发现

  • CRP(阈值5.0 mg/L)汇总敏感性0.45(95%CI 0.33-0.58),特异性0.83(95%CI 0.68-0.92)。
  • 粪便钙卫蛋白(阈值50 μg/g)敏感性0.76(95%CI 0.70-0.82),特异性0.66(95%CI 0.56-0.75)。
  • CTE/MRE敏感性0.89(95%CI 0.73-0.96),特异性0.65(95%CI 0.43-0.82)。
  • IUS敏感性0.92(95%CI 0.75-0.96),特异性0.76(95%CI 0.52-0.90)。
  • 采用优化的IUS放射学参数后,特异性提高至0.85(95%CI 0.71-0.93)。

关键数值与推荐

  • CRP阈值5.0 mg/L:敏感性0.45(95%CI 0.33-0.58),特异性0.83(95%CI 0.68-0.92)。
  • 粪便钙卫蛋白阈值50 μg/g:敏感性0.76(95%CI 0.70-0.82),特异性0.66(95%CI 0.56-0.75)。
  • CTE/MRE:敏感性0.89(95%CI 0.73-0.96),特异性0.65(95%CI 0.43-0.82)。
  • IUS:敏感性0.92(95%CI 0.75-0.96),特异性0.76(95%CI 0.52-0.90);优化IUS参数后特异性0.85(95%CI 0.71-0.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colonoscopy is recommended to monitor for Crohn's disease (CD) recurrence after surgical resection. However, repeated colonoscopy is invasive and resource-intensive. We conducted a systematic review and meta-analysis to evaluate the pooled diagnostic accuracy of noninvasive biomarkers and imaging measures for detecting endoscopic CD recurrence, as compared with colonoscopy. METHODS: A systematic review was conducted to January 31, 2024, to identify studies evaluating the diagnostic accuracy of C-reactive protein (CRP), fecal calprotectin, computed tomography and magnetic resonance enterography, or intestinal ultrasound (IUS) compared with colonoscopy for detecting CD recurrence. Estimates of sensitivity, specificity, and positive and negative likelihood ratios were pooled using a random-effects hierarchical summary receiver operating characteristic model. RESULTS: A total of 17 studies (N = 1080) evaluated inflammatory biomarkers and 20 studies (N = 1053) assessed imaging measures. The pooled sensitivity and specificity of CRP (threshold, 5.0 mg/L) were 0.45 (95% confidence interval [CI], 0.33-0.58) and 0.83 (95% CI, 0.68-0.92), respectively. Fecal calprotectin (threshold, 50 μg/g) was moderately sensitive 0.76 (95% CI, 0.70-0.82) but less specific 0.66 (95% CI, 0.56-0.75). Sensitivity for computed tomography enterography/magnetic resonance enterography and IUS was 0.89 (95% CI, 0.73-0.96) and 0.92 (95% CI, 0.75-0.96); specificity was 0.65 (95% CI, 0.43-0.82) and 0.76 (95% CI, 0.52-0.90), respectively. Using optimized radiographic parameters for IUS, specificity was improved to 0.85 (95% CI, 0.71-0.93). CONCLUSIONS: The high sensitivity of fecal calprotectin (<50 μg/g) and cross-sectional imaging can help reduce the need for invasive and costly colonoscopy monitoring for CD recurrence after surgery. Applying optimal definitions of sonographic recurrence by IUS parameters may further improve specificity for making therapeutic decisions without endoscopy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Samnani S, Ray CM, Gill P, et al. Diagnostic Accuracy of Noninvasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40467019. doi:10.1016/j.cgh.2025.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。